NASDAQ:CDNA
CareDx Stock News
$7.76
-0.440 (-5.37%)
At Close: Apr 30, 2024
CareDx Advances Artificial Intelligence in Transplantation
04:05pm, Thursday, 03'rd Jun 2021
Partnership with OrganX to develop decision support systems Partnership with OrganX to develop decision support systems
APA, Bloom Energy, NetApp and More Thursday Afternoon Analyst Calls
11:50am, Thursday, 03'rd Jun 2021
With the trading day about halfway over, the markets were sliding, with the tech sector getting the worst of it.
CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare
08:09am, Tuesday, 01'st Jun 2021
Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recip
CareDx Announces Strategic Minority Investment in Miromatrix
06:00pm, Friday, 28'th May 2021
Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs Participation in Series C and Research Partnership to Advance Development of Bioenginee
CareDx: The Market Leader In Organ Transplant Diagnostic Solutions/Software, With Strong Growth Prospects
03:58pm, Monday, 24'th May 2021
CareDx, Inc (CDNA) is dominating the organ transplant diagnostic solutions market, growing at 40% annually.
CareDx to Participate in AAKP and George Washington University Global Summit on Kidney Disease Innovations
07:00am, Thursday, 13'th May 2021
CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement
This Under-the-Radar Healthcare Company Quietly Surged During the Pandemic
10:15am, Friday, 07'th May 2021
CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.
CareDx, Inc.'s (CDNA) CEO Reginald Seeto on Q1 2021 Results - Earnings Call Transcript
09:08pm, Wednesday, 05'th May 2021
CareDx, Inc.'s (CDNA) CEO Reginald Seeto on Q1 2021 Results - Earnings Call Transcript
CareDx (CDNA) Q1 Earnings and Revenues Surpass Estimates
07:56pm, Wednesday, 05'th May 2021
CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ARK Genomic Revolution ETF: Value Realization Will Take Time
04:46am, Monday, 03'rd May 2021
ARK Genomic Revolution ETF: Value Realization Will Take Time
CareDx to Present New Heart Transplant Data at the International Society for Heart and Lung Transplantation Annual Meeting
07:00am, Friday, 23'rd Apr 2021
Renowned transplant clinicians to present 15 heart abstracts at ISHLT Renowned transplant clinicians to present 15 heart abstracts at ISHLT
Palmetto MolDx Issues Foundational Coverage for Molecular Testing in Solid Organ Allograft Rejection
11:38am, Thursday, 22'nd Apr 2021
Current Medicare coverage for CareDx services remains unchanged under the new universal coverage policy Current Medicare coverage for CareDx services remains unchanged under the new universal coverage
Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting Leading transplant clinicians to present data in seven abstra
CareDx to Report First Quarter 2021 Financial Results
04:00pm, Wednesday, 21'st Apr 2021
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021
07:00am, Tuesday, 20'th Apr 2021
Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians
